Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial

BACKGROUND: Bivalent mRNA-based COVID-19 vaccines encoding the ancestral and omicron spike (S) protein were developed as a countermeasure against antigenically distinct SARS-CoV-2 variants. We aimed to assess the (variant-specific) immunogenicity and reactogenicity of mRNA-based bivalent omicron (BA...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Ngoc H, Geers, Daryl, Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Boerma, Annemarie, Nijhof, Sander H, van Dort, Karel A, Koopmans, Marion P G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, van Baarle, Debbie, Zaeck, Luca M, GeurtsvanKessel, Corine H, de Vries, Rory D, van der Kuy, P Hugo M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188122/
https://www.ncbi.nlm.nih.gov/pubmed/37088096
http://dx.doi.org/10.1016/S1473-3099(23)00140-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188122/
https://www.ncbi.nlm.nih.gov/pubmed/37088096
http://dx.doi.org/10.1016/S1473-3099(23)00140-8

Ejemplares similares